Hydrochloric Acid

Hydrochloric Acid

SCHEMBL2260403

N#Cc1ccc(-[n+]2ccc(-c3cc[n+](Cc4ccccc4P(=O)(O)O)cc3)cc2)cc1.[Cl-].[Cl-]

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ ACHE known ✓ P22303 1/20 0.33
▸ PTPN5 P54829 1/20 0.35
▸ POLB P06746 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MEN1 O00255 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ SCN2A Q99250 1/20 0.30
▸ SCN10A Q9Y5Y9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2264053 0.87 ALDH1A1 (0.36) ACHEPOLBNPC1RAB9A
Hydrochloric Acid SCHEMBL2259575 0.85 RAB9A (0.45) PTPN5ACHEPOLBRAB9A
Hydrochloric Acid SCHEMBL3921996 0.85 POLB (0.31) ACHEPOLBNPC1RAB9A
Hydrochloric Acid SCHEMBL2259344 0.82 HTT (0.33) NPC1RAB9A
SCHEMBL4334655 0.81 MMP2 (0.33) MAPT
Hydrochloric Acid SCHEMBL2892896 0.79 RAB9A (0.38) ACHERAB9A
Hydrochloric Acid SCHEMBL3922774 0.78 — —
Hydrochloric Acid SCHEMBL604164 0.77 PTPN5 (0.38) PTPN5POLBMAPT
Hydrochloric Acid SCHEMBL601325 0.77 PTPN5 (0.36) PTPN5MEN1NPC1RAB9AKMT2A
Hydrochloric Acid SCHEMBL2260155 0.76 ALDH1A1 (0.51) MAPTMEN1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090259042-A1 ELECTROCHROMIC COMPOUNDS NTERA LIMITED (IE) 2009-10-15 — — US claimed
US-20060110638-A1 Electrochromic compounds NTERA LIMITED (IE) 2006-05-25 — — US claimed
EP-1443091-A1 Electrochromic compounds Ntera Limited (IE) 2004-08-04 — — EP claimed
US-8999430-B2 Method of manufacturing display element KONICA MINOLTA HOLDINGS, INC. (JP) 2015-04-07 — — US disclosed
EP-2149816-B1 METHOD OF MANUFACTURING AN ELECTROCHROMIC DISPLAY ELEMENT KONICA MINOLTA HOLDINGS INC (JP) 2014-05-07 — — EP disclosed
US-8014056-B2 Display element and method of driving the same KONICA MINOLTA HOLDINGS, INC. (JP) 2011-09-06 — — US disclosed
US-8004742-B2 Electrochromic display device KONICA MINOLTA HOLDINGS, INC. (JP) 2011-08-23 — — US disclosed
US-20100166946-A1 METHOD OF MANUFACTURING DISPLAY ELEMENT KONICA MINOLTA HOLDINGS, INC. (JP) 2010-07-01 — — US disclosed
US-20100091353-A1 DISPLAY ELEMENT AND METHOD OF DRIVING THE SAME KONICA MINOLTA HOLDINGS, INC. (JP) 2010-04-15 — — US disclosed
EP-2149816-A1 METHOD FOR PRODUCTION OF DISPLAY ELEMENT Konica Minolta Holdings, Inc. (JP) 2010-02-03 — — EP disclosed
US-20090316249-A1 ELECTROCHROMIC DISPLAY DEVICE KONICA MINOLTA HOLDINGS, INC. (JP) 2009-12-24 — — US disclosed
EP-2096490-A1 DISPLAY ELEMENT AND METHOD OF DRIVING THE SAME Konica Minolta Holdings, Inc. (JP) 2009-09-02 — — EP disclosed
US-7567371-B2 Electrochromic compounds NTERA LIMITED (IE) 2009-07-28 — — US disclosed
EP-2040115-A1 ELECTROCHROMIC DISPLAY DEVICE Konica Minolta Holdings, Inc. (JP) 2009-03-25 — — EP disclosed
US-20060110638-A1 Electrochromic compounds NTERA LIMITED (IE) 2006-05-25 — — US disclosed
EP-1443091-A1 Electrochromic compounds Ntera Limited (IE) 2004-08-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090259042-A1 ELECTROCHROMIC COMPOUNDS ETV6, HCN2, EED ACHE 161/4885PTPN5 2907/4885POLB 943/4885
US-20060110638-A1 Electrochromic compounds ETV6, HCN2, EED ACHE 161/4885PTPN5 2907/4885POLB 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback